10-Q: Oramed Pharmaceuticals Reports Q3 2024 Results, Strategic Review Underway

Oramed Pharmaceuticals reported its Q3 2024 results, highlighting a strategic review process and ongoing financial activities, including a significant transaction with Scilex Holding Company.

Summary

• Oramed Pharmaceuticals reported a net loss of $19.6 million for the three months ended September 30, 2024, and a net loss of $8.9 million for the nine months ended September 30, 2024.
• The company's research and development expenses decreased by 33% for the nine-month period, but increased by 134% for the three-month period due to new Phase 3 clinical trial preparations.
• General and administrative expenses decreased by 32% for the nine-month period and 67% for the three-month period, mainly due to the reversal of previously recognized expenses following the resignation of certain executive officers.
• The company's financial income decreased by 14% for the nine-month period, and turned into a loss of $15.4 million for the three-month period, primarily due to the revaluation of investments in Scilex.
• Oramed has been actively involved in transactions with Scilex, including a senior secured promissory note, warrants, and a recent refinancing agreement.
• The company is also pursuing a joint venture with HTIT Biotech to develop and commercialize products based on Oramed's oral drug delivery technology.
• As of September 30, 2024, Oramed had $42.1 million in cash and cash equivalents and $42.7 million in short-term deposits.
• The company believes it can maintain its current planned activities for at least the next 12 months based on current cash resources and commitments.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in strategic partnerships and has a strong cash position, the significant net losses and financial risks associated with the Scilex transactions temper the overall sentiment. The company is in a high-risk, high-reward situation.

Positives

• Oramed's cash and cash equivalents increased significantly to $42.1 million, providing a stronger financial position.
• The company is actively pursuing strategic opportunities, including a joint venture with HTIT Biotech, which could lead to future growth.
• Oramed has reduced its operating expenses in certain areas, such as general and administrative costs.
• The company has successfully refinanced a portion of its debt with Scilex and other investors.
• Oramed has secured a royalty agreement with Scilex, which could provide a future revenue stream.

Negatives

• Oramed reported a significant net loss of $19.6 million for the three months ended September 30, 2024.
• The company experienced a substantial financial loss of $15.4 million for the three-month period due to the revaluation of investments in Scilex.
• The company's research and development expenses increased significantly in the three-month period, indicating higher spending.
• Oramed has not generated significant revenues from its operations.
• The company's previous Phase 3 trials for oral insulin did not meet their primary or secondary endpoints.

Risks

• The company's future success is dependent on the successful development and commercialization of its products.
• Oramed is subject to the risks associated with the biotechnology industry, including clinical trial failures and regulatory hurdles.
• The company's financial performance is heavily influenced by its investments in Scilex, which are subject to market fluctuations.
• The joint venture with HTIT Biotech is contingent upon the parties entering into additional agreements, which may not occur.
• The company is exposed to potential litigation and the political, economic and military risks of having operations in Israel.

Future Outlook

Oramed expects that research and development expenses will continue to be its major operating expense in the upcoming years, but this may change due to the new Phase 3 clinical trial and the current strategic review. The company believes it can maintain its current planned activities for at least the next 12 months based on current cash resources and commitments.

Management Comments

• The company is examining its existing pipeline and has commenced an evaluation process of potential strategic opportunities, with the goal of enhancing value for its stockholders.
• The company believes it will be able to maintain its current planned activities and the corresponding level of expenditures for at least the next 12 months.

Industry Context

Oramed's focus on oral drug delivery technology aligns with the broader industry trend of seeking more patient-friendly and convenient drug administration methods. The company's efforts to develop an oral insulin capsule address a significant unmet need in the diabetes market. The strategic review and joint venture indicate a proactive approach to navigating the competitive landscape and leveraging its technology.

Comparison to Industry Standards

• Oramed's financial performance is mixed compared to other biotech companies in the development stage. While the company has a strong cash position, its significant net losses and reliance on external financing are typical of companies in this sector.
• The company's strategic review and joint venture are similar to actions taken by other biotech firms to optimize their pipelines and secure funding.
• The company's focus on oral drug delivery is a differentiating factor, but the success of this technology is still uncertain.
• Compared to companies like Novo Nordisk and Eli Lilly, which have established insulin products, Oramed is still in the development phase and faces significant challenges in bringing its product to market.
• The company's recent transactions with Scilex are complex and involve significant financial risks, which is not uncommon for biotech companies seeking to raise capital and monetize assets.

Related Party Transactions

• The Subsidiary has a consulting agreement with KNRY Ltd., owned by the Chief Scientific Officer.
• The company has a consulting agreement with Shnida Ltd., through which the President and Chief Executive Officer provides services.

Stakeholder Impact

• Shareholders are impacted by the company's net losses and the volatility of its investments.
• Employees are affected by the company's strategic review and potential changes in operations.
• Customers and patients are impacted by the company's progress in developing new treatments.
• Suppliers and creditors are affected by the company's financial condition and ability to meet its obligations.

Next Steps

• Oramed will continue to evaluate potential strategic opportunities.
• The company will continue to work towards the consummation of the joint venture agreement with HTIT Biotech.
• Oramed will continue to develop its oral insulin and POD technology.
• The company will continue to monitor the situation in Israel and its potential impact on business operations.
• Oramed will continue to pursue the new Phase 3 clinical trial for its oral insulin capsule candidate.

Key Dates

Keywords

Oramed Pharmaceuticals, oral insulin, biotechnology, clinical trials, Scilex Holding Company, joint venture, HTIT Biotech, financial results, strategic review, debt refinancing